Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ORCHID PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ORCHID PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
ORCHID PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 439 | 314 | - | |
Low | Rs | 273 | 226 | - | |
Sales per share (Unadj.) | Rs | 163.1 | 93.4 | - | |
Earnings per share (Unadj.) | Rs | 13.5 | -23.5 | - | |
Cash flow per share (Unadj.) | Rs | 27.0 | -19.5 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 168.7 | 73.3 | - | |
Shares outstanding (eoy) | m | 40.82 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.2 | 2.9 | 75.4% | |
Avg P/E ratio | x | 26.3 | -11.5 | -228.9% | |
P/CF ratio (eoy) | x | 13.2 | -13.9 | -95.3% | |
Price / Book Value ratio | x | 2.1 | 3.7 | 57.2% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 14,522 | 45,603 | 31.8% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 654 | 2,862 | 22.8% | |
Avg. sales/employee | Rs Th | 0 | 3,671.4 | - | |
Avg. wages/employee | Rs Th | 0 | 666.7 | - | |
Avg. net profit/employee | Rs Th | 0 | -925.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,659 | 15,761 | 42.2% | |
Other income | Rs m | 194 | 110 | 176.1% | |
Total revenues | Rs m | 6,853 | 15,872 | 43.2% | |
Gross profit | Rs m | 1,235 | -2,731 | -45.2% | |
Depreciation | Rs m | 548 | 680 | 80.5% | |
Interest | Rs m | 329 | 427 | 77.1% | |
Profit before tax | Rs m | 552 | -3,728 | -14.8% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 233 | 0.0% | |
Profit after tax | Rs m | 552 | -3,971 | -13.9% | |
Gross profit margin | % | 18.5 | -17.3 | -107.0% | |
Effective tax rate | % | 0 | -6.2 | -0.0% | |
Net profit margin | % | 8.3 | -25.2 | -32.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 5,010 | 11,544 | 43.4% | |
Current liabilities | Rs m | 3,719 | 6,495 | 57.3% | |
Net working cap to sales | % | 19.4 | 32.0 | 60.5% | |
Current ratio | x | 1.3 | 1.8 | 75.8% | |
Inventory Days | Days | 57 | 111 | 51.7% | |
Debtors Days | Days | 1,180 | 124 | 951.7% | |
Net fixed assets | Rs m | 7,242 | 6,729 | 107.6% | |
Share capital | Rs m | 408 | 73 | 557.8% | |
Net worth | Rs m | 6,886 | 12,371 | 55.7% | |
Long term debt | Rs m | 1,488 | 4,347 | 34.2% | |
Total assets | Rs m | 12,252 | 23,369 | 52.4% | |
Interest coverage | x | 2.7 | -7.7 | -34.6% | |
Debt to equity ratio | x | 0.2 | 0.4 | 61.5% | |
Sales to assets ratio | x | 0.5 | 0.7 | 80.6% | |
Return on assets | % | 7.2 | -15.2 | -47.4% | |
Return on equity | % | 8.0 | -32.1 | -25.0% | |
Return on capital | % | 10.5 | -19.8 | -53.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 183 | 1,345 | 13.6% | |
From Investments | Rs m | -312 | -413 | 75.6% | |
From Financial Activity | Rs m | 312 | 3,945 | 7.9% | |
Net Cashflow | Rs m | 183 | 4,878 | 3.7% |
Compare ORCHID PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare ORCHID PHARMA With: GRANULES INDIA ZYDUS LIFESCIENCES ADVIK LABORS EARUM PHARMACEUTICALS KOPRAN.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.